Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
30.4M
-
Shares change
-
+1.5M
-
Total reported value, excl. options
-
$302M
-
Value change
-
+$13.4M
-
Put/Call ratio
-
0.73
-
Number of buys
-
44
-
Number of sells
-
-45
-
Price
-
$9.94
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2022
117 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q1 2022.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.4M shares
.
Largest 10 shareholders include PICTET ASSET MANAGEMENT SA (3.53M shares), BlackRock Inc. (3.49M shares), VANGUARD GROUP INC (3.01M shares), HHLR ADVISORS, LTD. (2.92M shares), BAKER BROS. ADVISORS LP (2.8M shares), ArrowMark Colorado Holdings LLC (1.32M shares), Hudson Bay Capital Management LP (1.28M shares), GREAT POINT PARTNERS LLC (1.12M shares), Opaleye Management Inc. (1.11M shares), and MILLENNIUM MANAGEMENT LLC (988K shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.